The main purpose of this legislation is to speed up the process for patients in the United States to access new and innovative medicines and participate in clinical trials for life-threatening diseases. It aims to do this by creating a system that allows for reciprocal approval of drugs and clinical trials with trusted international regulatory authorities. This means that if a drug is approved in another country by a recognized regulatory body, it can be approved more quickly in the U.S.